Saturday November 14th: 8:00 a.m. – 1:30 p.m. EST
Stuart B. Johnson, MD, FIDSA, DTM&H
Conference Co-Chair & Keynote Speaker
Dr. Johnson, MD, FIDSA, DTM&H, Professor, Department of Medicine, Stritch School of Medicine, Loyola University, Chicago, IL. Dr. Stuart Johnson, MD is a Professor of Medicine at Loyola University Stritch School of Medicine at Loyola University Medical Center and a Researcher at the Hines VA Hospital, Chicago, Illinois. His main research interest and focus has involved the epidemiology pathogenesis and treatment of Clostridium difficile infection. He is actively studying variant strains of C. difficile and the role of the various toxins in the pathogenesis of C. difficile disease. His clinical experience in the treatment of patients with recurrent CDI has translated into studies helping to define optimal management of these infections, including the utility and pitfalls of alternative treatment agents. He is currently the Principal Investigator of a multi-center study with the VA Healthcare system designed to define optimal management of early
recurrences of CDI.
Dale Gerding, MD, FACP, FIDSA
Dr. Gerding, MD, FACP, FIDSA, Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois and Research Physician at the Edward Hines Jr. VA Hospital. Before his present position, Dr. Gerding was Chief of Medicine at VA Chicago, Lakeside Division, and Professor of Medicine at Northwestern University Feinberg School of Medicine. He is an infectious disease specialist and hospital epidemiologist, past president of the Society for Healthcare Epidemiology of America (SHEA), and past chair the antibiotic resistance committee of SHEA. He is a fellow of the Infectious Diseases Society of America (IDSA) and past Chair of the National and Global Public Health Committee and the Antibiotic Resistance Subcommittee of IDS
Paul Feuerstadt, MD, FACG
Conference Co-Chair & Keynote Speaker
Dr. Feuerstadt, MD, FACG, is a Native of Long Island, New York.
Dr. Feuerstadt attended the University of Pennsylvania where he earned his Bachelor of Arts degree in Biology, with distinction in research and graduated Summa Cum Laude. Following the completion of his undergraduate training,
Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan, New York where he earned his Medical Doctor degree and stayed at New York-Presbyterian Hospital/Weill Cornell medical center for his internship and residency in Internal Medicine. Following the completion of his residency, Dr. Feuerstadt then moved on to the Montefiore Medical Center in the Bronx, NY for his clinical fellowship training. His areas of interest include ischemic diseases of the gut and chronic diarrheal syndromes with a specific focus on C.diff. infections. Dr.Feuerstadt is affiliated with the St. Raphael campus of Yale-New Haven Hospital, Yale-New Haven Hospital, and Milford Hospital seeing outpatients in his offices in Hamden and Milford, CT
Erik R. Dubberke, MD, MSPH
Dr. Dubberke, MD, MSPH is an Associate Professor of Medicine at Washington University School of Medicine in St. Louis, where he has been a faculty member in the Division of Infectious Diseases since 2005. He is an Associate Hospital Epidemiologist at Barnes-Jewish Hospital, Medical Director of Infection Control at Missouri Baptist Medical Center, and is the Director of the Section of Transplant Infectious Diseases at Washington University. He attended medical school at the University of Illinois at Chicago and did his medicine and infectious diseases training at Barnes-Jewish Hospital/Washington University. He received a Master’s of Science in Public Health from St. Louis University. His main research interests are in the epidemiology, diagnosis, treatment, and prevention of Clostridium difficile infection (CDI). Dr. Dubberke has over 115 publications and made the Thomson Reuters list of Highly Cited Researchers in 2015 and 2016. He was the lead author for the CDI component of the Society for Healthcare Epidemiology of America (SHEA) Compendium to Prevent Healthcare-Associated Infections and is on the panel updating the SHEA/IDSA CDI clinical guidelines. He has also represented SHEA as a Key Informant for the AHRQ Evidence-based Practice Center C. difficile review and at the Department of Health and Human Services Road Map to Eliminate HAI 2013 Action Plan Conference.
Presentation Topic: TBA
Glenn S. Tillotson, Ph.D., FRSM, FCCP
Dr. Tillotson, Ph.D., FRSM, FCCP has 30+ years of pharmaceutical experience in early pre-clinical and clinical research, commercialization, medical affairs, scientific communications including publication planning strategic drug development, life cycle management, and global launch programs. Dr. Tillotson has been instrumental in the development and launch of ciprofloxacin, moxifloxacin, gemifloxacin, and other antibacterials. Glenn has held several key committee positions at the American College of Chest Physicians; he is on the Scientific Steering Committee for the GTCBio. Annual Summit on Anti-infective Partnering. Currently, Dr. Tillotson has published >140 peer-reviewed manuscripts, presented >270 scientific posters, and is on several journals Editorial Advisory Boards including the Lancet Infectious Disease, eBioMedicine, and F1000.
Presentation Topic: Antibiotic Stewardship
C. diff. Survivors
C. diff. Survivors join us to share personal C. difficile infection journey; The signs, symptoms, treatments, with the physical, mental, and psycho-social changes and losses endured from this life-threatening infection and how each recurrent C. difficile infection (rCDI) impacted their lives. Kathy Bischoff, Dayle Skelly
Presentation Topic: “C. diff. Survivor’s Journey. “
Seres Therapeutics Will Be Presenting. Presentation Topic: TBA
Sahil Khanna, MD, M.B.B.S
Dr. Khanna, MD, MBBS, is an Assistant Professor of Medicine in the Division of Gastroenterology and Hepatology at Mayo Clinic, Rochester, MN. His completed Medical School at the All India Institute of Medical Sciences, New Delhi; followed by Post Doctoral Research at the University of California, San Diego, CA; residency in Internal Medicine and Fellowship in Gastroenterology and Hepatology at Mayo Clinic, Rochester, MN before joining the Faculty. Dr. Khanna has completed a Masters in Clinical and Translational Sciences during his fellowship. His research and clinical interests include Epidemiology, Outcomes, and Emerging Therapeutics for Clostridium difficile infection, an arena in which he has had numerous publications and presentations. He is directing the C. difficile Clinic, Fecal Microbiota Transplantation program, and C. difficile related Clinical Trials at the May Clinic, Rochester, MN.
Presentation Topic: TBA
Professor Mark Wilcox, MD, FRCPath Dr. Wilcox is the Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology at the Leeds Teaching Hospitals (LTHT), Professor of Medical Microbiology at the University of Leeds at their Institute of Biomedical and Clinical Sciences, and is the lead on Clostridium difficile for Public Health, in England in the UK. He was Director of Infection Prevention, and Control, Doctor and Clinical Director of Pathology at LTHT. Dr. Wilcox is deputy Chair of the UK Department of Health’s Antimicrobial Resistance and Healthcare-Associated Infection Committee and is a member of the HPA’s Program Board on Healthcare-Associated Infection & Antimicrobial Resistance. He has a track record of translational research, including providing the basis of clinical advice to the NHS. He has been the Principal/UK Investigator for several clinical trials of new anti-infective drugs and has provided clinical advice as part of the FDA/EMA submissions for the approval of several novel antimicrobial agents. Presentation Topic: TBA
Caterina Oneto, MD C. diff. Global TeleSupport Program, Co-Director Dr. Caterina Oneto is a Clinical Assistant Professor within the NYU Division of Gastroenterology, Board Certified in Gastroenterology and Internal Medicine. Dr. Oneto is fluent in Spanish. She graduated with a degree in Medicine and Surgery from the Universidad de Valparaiso in Chile and completed her residency in
Internal Medicine at Cabrini Medical Center, where she served also as Chief Resident, and later completed her Fellowship in Gastroenterology at Montefiore Medical Center, Albert Einstein College of Medicine. With expertise in endoscopy, colonoscopy, capsule endoscopy, liver, and pancreatic diseases, Dr. Oneto’s special interests include IBD (Crohn’s disease and Ulcerative Colitis), IBS (irritable bowel syndrome), microbiota modification, treatment of Clostridioides difficile, and FMT (Fecal Microbiota Transplantation). Presentation Topic: Introduction to Global TeleSupport Program & More.
Teena Chopra, MD, FIDSA – Junior Infection Fighters Program, Co-Director of Infection Prevention Education. Dr. Chopra is a Professor of Medicine in the Division of Infectious Diseases, at Wayne State University and the Corporate Medical Director of Hospital Epidemiology, Infection Prevention, and Antibiotic Stewardship at Detroit Medical Center, Wayne State University. Her research interests include Epidemiology of Healthcare-associated Infections, Infection Prevention Antibiotic Stewardship, and Immunization. Dr. Chopra has published over 70 papers in various journals and book chapters. Additionally, she has independently reviewed over 50 journal articles. Dr. Chopra has a special interest in studying the epidemiology of infections, including Clostridium difficile and Multi-Drug Resistant Organisms. Presentation Topic: Introduction to the Junior Infection Fighters Educational Program.
David Lyerly, Ph.D. is the co-founder and Chief Science Officer of TECHLAB, Inc. He received his B.S. from UNC-Chapel Hill and his Ph.D. in Microbiology/Immunology from Wake Forest Bowman Gray School of Medicine. He and Dr. Tracy Wilkins founded TECHLAB in 1989. TECHLAB focuses on innovative diagnostic solutions for C. difficile, other enteric diseases, and intestinal inflammation. Presentation Topic: TBA
Maureen Spencer, RN, M.Ed. CIC has been an Infection Preventionist for over 40 years and is board certified in infection control (CIC). As one of the early pioneers in infection control, she was awarded the APIC National Carole DeMille Award in 1990 and was selected as one of the APIC Heroes of Infection Prevention in 2007 for her work in establishing a MRSA and Staph aureus Elimination Program at New England Baptist Hospital, an Orthopedic Center of Excellence in Boston. The groundbreaking work was published in the Journal of Bone and Joint Surgery, Aug 2010. In 2012 she was selected as one of the “Who’s Who of Infection Prevention” and in 2017 she was recognized as a Fellow of the Association for Professionals in Infection Control and Epidemiology (FAPIC) for her advanced practice in infection prevention and leader within the field. Presentation Topic: TBA
S P O N S O R S
We are truly grateful for the participation and sponsorships by the organizations that are continuously researching, developing, and addressing healthcare-associated infections worldwide. Many with a primary focus and goal to prevent, treat, and diagnose a leading HAI; Clostridioides difficile (C. diff., C. difficile, CDI) infections and we applaud their dedication in the C. diff. community.
To learn more about the Sponsors, please click on the graphics displayed below. Thank you.
ABSTRACTS ARE BEING ACCEPTED FOR REVIEW
Through October 2nd.
Dr. Kerrie Davies, Ph. D.
Dr. Edmond Hooker, MD, DrPH
Maureen Spencer, RN, M.Ed., CIC
Please forward information to firstname.lastname@example.org
2020 – AWARDS
Please contact Angelo Ortiz for more information email@example.com